Recent investments completed by CCG::
Oval Medical Technologies Ltd. - autoinjector development;
| www.ovalmedical.com |
Augmentra - GPS based mapping applications for mobile devices;
| www.augmentra.com |
Base 4 Innovation - solid state DNA sequencing;
| www.base4innovation.co.uk |
Pneumacare - non invasive assessment of lung function;
| www.pneumacare.com |
GenDrive - grid connected inverters;
| www.gendrive.co.uk |
Urosens - bladder cancer screening;
| www.urosens.com |
Enval - aluminium reclamation from packaging waste;
| www.enval.com |
Ubisense Ltd – high precision, real-time location tracking of high value assets;
| www.ubisense.net |
Camfridge - next generation refrigeration technology;
| www.camfridge.com |
Light Blue Optics - miniature video projection systems;
| www.lightblueoptics.com |
Metalysis - refining of high value metals and alloys;
| www.metalysis.com |
Nujira - efficient power amplifier technology for wireless markets;
| www.nujira.com |
Inotec AMD Ltd – wound healing technologies;
| www.inotecamd.com |
3T Technologies Ltd – thin-film, transparent transistor technology;
| www.3ttechnologies.com |
Cambridge Temperature Concepts Ltd - fertility prediction;
| www.temperatureconcepts.com |
Phico Therapeutics - modified phage based therapeutic platform;
| www.phicotherapeutics.co.uk |
To date, our investors have made more than 35 investments in a wide range of technology sectors. Our portfolio has seen two good exits in recent years with several other strong candidates coming through to commercialisation.
Cambridge Capital Group is well integrated into the early-stage investment scene. We co-invest with the leading private and institutional technology investors, and enjoy a deal flow from a range of sources, including the members' own networks in south-east England and East Anglia.
We seek strong propositions at seed or start-up stage in high technology sectors, usually based on the physical sciences; our investors are looking for disruptive technologies with large niche or broad international markets. However, we will consider non-technology projects if they are well-differentiated with attractive markets, and come recommended from one of the members or the lead investor.
